2. Academic Validation
  3. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors

Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors

  • J Med Chem. 2008 Nov 27;51(22):7049-52. doi: 10.1021/jm801050k.
Savithri Ramurthy 1,  Sharadha Subramanian,  Mina Aikawa,  Payman Amiri,  Abran Costales,  Jeff Dove,  Susan Fong,  Johanna M Jansen,  Barry Levine,  Sylvia Ma,  Christopher M McBride,  Jonah Michaelian,  Teresa Pick,  Daniel J Poon,  Sandhya Girish,  Cynthia M Shafer,  Darrin Stuart,  Leonard Sung,  Paul A Renhowe
Affiliations

Affiliation

  • 1 Novartis Institutes for Biomedical Research, 4560 Horton Street, Emeryville, California 94608, USA. savithri.ramurthy@novartis.com
PMID: 18942827 DOI: 10.1021/jm801050k
Abstract

A series of arylaminobenzimidazoles was designed and synthesized as Raf kinase inhibitors. Exploration of the structure-activity relationship resulted in compounds that are potent in vitro and show desirable in vivo properties.

Figures